Evidence map›Paper›PMID 36575250›Full record

ArticleJournal of medical toxicology : official journal of the American College of Medical Toxicology2023

Diphenhydramine-Induced Antimuscarinic Delirium Treated with Physostigmine and Transdermal Rivastigmine.

James D Whitledge, C James Watson, Michael Simpson, Azza Bakkar, Leora Boussi, Michael Scott, Katherine L Boyle

Open access · greenAbstract readCase Reports
In one paragraph

Article in Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Toxidromes.Nature reviews. Disease primers · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

James D WhitledgeHarvard Medical Toxicology Fellowship, Boston, MA, USA. james.whitledge@childrens.harvard.edu.ORCID 0000-0002-6927-4427
C James WatsonHarvard Medical Toxicology Fellowship, Boston, MA, USA.
Michael SimpsonHarvard Medical Toxicology Fellowship, Boston, MA, USA.
Azza BakkarDepartment of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Leora BoussiDepartment of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Michael ScottDepartment of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Katherine L BoyleHarvard Medical Toxicology Fellowship, Boston, MA, USA.
Beth Israel Deaconess Medical Center · USBrigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecurrent physostigmine shortages present a challenge to healthcare providers treating antimuscarinic delirium. Other centrally acting acetylcholinesterase inhibitors such as rivastigmine may represent a therapeutic alternative or adjunct during physostigmine shortage; however, previous reports of use have not documented serum antimuscarinic toxin concentrations, limiting evaluation of effectiveness. Combination therapy with physostigmine and rivastigmine has not been described. In this report, the authors present a case of diphenhydramine-induced antimuscarinic delirium with elevated diphenhydramine serum concentrations treated with physostigmine and transdermal rivastigmine without observed adverse effect. CASE REPORT: A 48-year-old female presented to an emergency department after ingesting 3.75 g (41.2 mg/kg) of diphenhydramine. She had antimuscarinic delirium with a presenting serum diphenhydramine concentration of 1500 ng/mL (therapeutic range, 25-112 ng/mL) and required two doses of physostigmine to avert intubation prior to intensive care unit (ICU) admission. At hospital hour 22, in the ICU, antimuscarinic delirium persisted but no further physostigmine was available due to hospital shortage. Therefore, a 9.5-mg transdermal rivastigmine patch was applied. By hospital hour 24, her delirium had resolved. A serum diphenhydramine concentration at hospital hour 25 was elevated at 760 ng/mL. Transdermal rivastigmine was discontinued at hospital hour 48 without recurrent delirium. Despite persistent normal mental status after rivastigmine discontinuation, the patient had a dry mouth, difficulty urinating, and mydriasis until hospital day 5. She never developed muscarinic toxicity. DISCUSSION: Transdermal rivastigmine may be a useful treatment alternative or adjunct during physostigmine shortage for antimuscarinic delirium and has a long duration of action without aspiration risk. Muscarinic toxicity was not observed.

Indexed as

DeliriumPhysostigmineAcetylcholinesteraseCholinesterase InhibitorsFemaleHumansMiddle AgedMuscarinic AntagonistsRivastigmineAcetylcholinesteraseCholinesterase InhibitorsMuscarinic AntagonistsPhysostigmineRivastigmineAntimuscarinic deliriumDiphenhydraminePhysostigmineRivastigmineTransdermal

Identifiers

PMID36575250
PMCPMC10050648
OpenAlexW4313237416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.